Insider Transactions in Q2 2023 at Kal Vista Pharmaceuticals, Inc. (KALV)
Insider Transaction List (Q2 2023)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
May 18
2023
|
Christopher Yea CHIEF DEVELOPMENT OFFICER |
SELL
Open market or private sale
|
Direct |
2,604
-6.52%
|
$26,040
$10.14 P/Share
|
|
May 18
2023
|
Paul K. Audhya CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Direct |
2,780
-17.6%
|
$27,800
$10.14 P/Share
|
|
May 18
2023
|
Thomas Andrew Crockett CEO |
SELL
Open market or private sale
|
Direct |
5,627
-4.21%
|
$56,270
$10.14 P/Share
|
|
May 18
2023
|
Edward P. Feener CHIEF SCIENTIFIC OFFICER |
SELL
Open market or private sale
|
Direct |
1,786
-2.61%
|
$17,860
$10.14 P/Share
|
|
May 18
2023
|
Benjamin L Palleiko CHIEF EXECUTIVE OFFICER |
SELL
Open market or private sale
|
Direct |
4,037
-4.91%
|
$40,370
$10.14 P/Share
|
|
May 17
2023
|
Christopher Yea CHIEF DEVELOPMENT OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
4,205
+9.53%
|
-
|
|
May 17
2023
|
Paul K. Audhya CHIEF MEDICAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
6,447
+28.99%
|
-
|
|
May 17
2023
|
Thomas Andrew Crockett CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
12,750
+8.71%
|
-
|
|
May 17
2023
|
Edward P. Feener CHIEF SCIENTIFIC OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
4,205
+5.78%
|
-
|
|
May 17
2023
|
Benjamin L Palleiko CHIEF EXECUTIVE OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
9,364
+10.23%
|
-
|